nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Fingolimod—multiple sclerosis	0.087	0.246	CbGbCtD
Pimecrolimus—CYP3A4—Methylprednisolone—multiple sclerosis	0.0561	0.158	CbGbCtD
Pimecrolimus—CYP3A4—Triamcinolone—multiple sclerosis	0.0425	0.12	CbGbCtD
Pimecrolimus—CYP3A4—Mitoxantrone—multiple sclerosis	0.0409	0.116	CbGbCtD
Pimecrolimus—CYP3A4—Betamethasone—multiple sclerosis	0.0365	0.103	CbGbCtD
Pimecrolimus—CYP3A4—Prednisolone—multiple sclerosis	0.036	0.102	CbGbCtD
Pimecrolimus—CYP3A4—Prednisone—multiple sclerosis	0.034	0.0959	CbGbCtD
Pimecrolimus—MTOR—leg—multiple sclerosis	0.023	0.319	CbGeAlD
Pimecrolimus—CYP3A4—Dexamethasone—multiple sclerosis	0.0212	0.0599	CbGbCtD
Pimecrolimus—MTOR—brainstem—multiple sclerosis	0.00536	0.0743	CbGeAlD
Pimecrolimus—MTOR—retina—multiple sclerosis	0.00517	0.0717	CbGeAlD
Pimecrolimus—FKBP1A—retina—multiple sclerosis	0.00465	0.0645	CbGeAlD
Pimecrolimus—FKBP1A—medulla oblongata—multiple sclerosis	0.00336	0.0466	CbGeAlD
Pimecrolimus—MTOR—spinal cord—multiple sclerosis	0.00333	0.0462	CbGeAlD
Pimecrolimus—FKBP1A—midbrain—multiple sclerosis	0.00307	0.0426	CbGeAlD
Pimecrolimus—FKBP1A—spinal cord—multiple sclerosis	0.003	0.0416	CbGeAlD
Pimecrolimus—MTOR—nervous system—multiple sclerosis	0.00281	0.0389	CbGeAlD
Pimecrolimus—MTOR—central nervous system—multiple sclerosis	0.0027	0.0375	CbGeAlD
Pimecrolimus—MTOR—cerebellum—multiple sclerosis	0.00264	0.0366	CbGeAlD
Pimecrolimus—FKBP1A—nervous system—multiple sclerosis	0.00252	0.035	CbGeAlD
Pimecrolimus—FKBP1A—central nervous system—multiple sclerosis	0.00243	0.0337	CbGeAlD
Pimecrolimus—FKBP1A—cerebellum—multiple sclerosis	0.00238	0.033	CbGeAlD
Pimecrolimus—MTOR—brain—multiple sclerosis	0.00215	0.0298	CbGeAlD
Pimecrolimus—FKBP1A—brain—multiple sclerosis	0.00193	0.0268	CbGeAlD
Pimecrolimus—CYP3A4—nervous system—multiple sclerosis	0.000825	0.0114	CbGeAlD
Pimecrolimus—CYP3A4—central nervous system—multiple sclerosis	0.000794	0.011	CbGeAlD
Pimecrolimus—Nervous system disorder—Cladribine—multiple sclerosis	0.00068	0.00197	CcSEcCtD
Pimecrolimus—Skin disorder—Cladribine—multiple sclerosis	0.000673	0.00195	CcSEcCtD
Pimecrolimus—Sinusitis—Mitoxantrone—multiple sclerosis	0.00067	0.00194	CcSEcCtD
Pimecrolimus—Rhinitis—Mitoxantrone—multiple sclerosis	0.000643	0.00186	CcSEcCtD
Pimecrolimus—Pharyngitis—Mitoxantrone—multiple sclerosis	0.000636	0.00184	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000631	0.00183	CcSEcCtD
Pimecrolimus—Breast disorder—Methylprednisolone—multiple sclerosis	0.00063	0.00182	CcSEcCtD
Pimecrolimus—Paraesthesia—Cladribine—multiple sclerosis	0.000622	0.0018	CcSEcCtD
Pimecrolimus—Dyspnoea—Cladribine—multiple sclerosis	0.000618	0.00179	CcSEcCtD
Pimecrolimus—Skin exfoliation—Methotrexate—multiple sclerosis	0.000607	0.00176	CcSEcCtD
Pimecrolimus—Influenza—Triamcinolone—multiple sclerosis	0.000604	0.00175	CcSEcCtD
Pimecrolimus—Asthma—Triamcinolone—multiple sclerosis	0.000604	0.00175	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000598	0.00173	CcSEcCtD
Pimecrolimus—Constipation—Cladribine—multiple sclerosis	0.000593	0.00171	CcSEcCtD
Pimecrolimus—Pain—Cladribine—multiple sclerosis	0.000593	0.00171	CcSEcCtD
Pimecrolimus—Arthralgia—Azathioprine—multiple sclerosis	0.000588	0.0017	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000584	0.00169	CcSEcCtD
Pimecrolimus—Bronchitis—Triamcinolone—multiple sclerosis	0.000581	0.00168	CcSEcCtD
Pimecrolimus—Conjunctivitis—Prednisolone—multiple sclerosis	0.000569	0.00165	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000567	0.00164	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000562	0.00162	CcSEcCtD
Pimecrolimus—Infection—Azathioprine—multiple sclerosis	0.00056	0.00162	CcSEcCtD
Pimecrolimus—Erythema—Mitoxantrone—multiple sclerosis	0.000558	0.00161	CcSEcCtD
Pimecrolimus—Urticaria—Cladribine—multiple sclerosis	0.00055	0.00159	CcSEcCtD
Pimecrolimus—Abdominal pain—Cladribine—multiple sclerosis	0.000548	0.00158	CcSEcCtD
Pimecrolimus—Body temperature increased—Cladribine—multiple sclerosis	0.000548	0.00158	CcSEcCtD
Pimecrolimus—Skin disorder—Azathioprine—multiple sclerosis	0.000547	0.00158	CcSEcCtD
Pimecrolimus—Back pain—Mitoxantrone—multiple sclerosis	0.00054	0.00156	CcSEcCtD
Pimecrolimus—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000538	0.00156	CcSEcCtD
Pimecrolimus—Infestation—Methylprednisolone—multiple sclerosis	0.000538	0.00156	CcSEcCtD
Pimecrolimus—Face oedema—Prednisone—multiple sclerosis	0.000533	0.00154	CcSEcCtD
Pimecrolimus—Conjunctivitis—Triamcinolone—multiple sclerosis	0.000524	0.00152	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000513	0.00149	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cladribine—multiple sclerosis	0.000511	0.00148	CcSEcCtD
Pimecrolimus—Epistaxis—Triamcinolone—multiple sclerosis	0.000508	0.00147	CcSEcCtD
Pimecrolimus—Pruritus—Cladribine—multiple sclerosis	0.00049	0.00142	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Methotrexate—multiple sclerosis	0.000489	0.00142	CcSEcCtD
Pimecrolimus—Cough—Mitoxantrone—multiple sclerosis	0.000487	0.00141	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000486	0.00141	CcSEcCtD
Pimecrolimus—Rhinitis—Triamcinolone—multiple sclerosis	0.000485	0.0014	CcSEcCtD
Pimecrolimus—Rhinitis—Methylprednisolone—multiple sclerosis	0.000484	0.0014	CcSEcCtD
Pimecrolimus—Pharyngitis—Triamcinolone—multiple sclerosis	0.00048	0.00139	CcSEcCtD
Pimecrolimus—Conjunctivitis—Dexamethasone—multiple sclerosis	0.000475	0.00137	CcSEcCtD
Pimecrolimus—Conjunctivitis—Betamethasone—multiple sclerosis	0.000475	0.00137	CcSEcCtD
Pimecrolimus—Arthralgia—Mitoxantrone—multiple sclerosis	0.000475	0.00137	CcSEcCtD
Pimecrolimus—Diarrhoea—Cladribine—multiple sclerosis	0.000474	0.00137	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000461	0.00133	CcSEcCtD
Pimecrolimus—Erythema—Prednisolone—multiple sclerosis	0.000458	0.00132	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000455	0.00132	CcSEcCtD
Pimecrolimus—Oedema—Mitoxantrone—multiple sclerosis	0.000455	0.00132	CcSEcCtD
Pimecrolimus—Infection—Mitoxantrone—multiple sclerosis	0.000452	0.00131	CcSEcCtD
Pimecrolimus—Eye disorder—Methylprednisolone—multiple sclerosis	0.000451	0.0013	CcSEcCtD
Pimecrolimus—Abdominal pain—Azathioprine—multiple sclerosis	0.000445	0.00129	CcSEcCtD
Pimecrolimus—Body temperature increased—Azathioprine—multiple sclerosis	0.000445	0.00129	CcSEcCtD
Pimecrolimus—Skin disorder—Mitoxantrone—multiple sclerosis	0.000442	0.00128	CcSEcCtD
Pimecrolimus—Vomiting—Cladribine—multiple sclerosis	0.000441	0.00127	CcSEcCtD
Pimecrolimus—Rash—Cladribine—multiple sclerosis	0.000437	0.00126	CcSEcCtD
Pimecrolimus—Dermatitis—Cladribine—multiple sclerosis	0.000436	0.00126	CcSEcCtD
Pimecrolimus—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000436	0.00126	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000435	0.00126	CcSEcCtD
Pimecrolimus—Headache—Cladribine—multiple sclerosis	0.000434	0.00126	CcSEcCtD
Pimecrolimus—Erythema—Triamcinolone—multiple sclerosis	0.000421	0.00122	CcSEcCtD
Pimecrolimus—Malnutrition—Methylprednisolone—multiple sclerosis	0.00042	0.00122	CcSEcCtD
Pimecrolimus—Erythema—Methylprednisolone—multiple sclerosis	0.00042	0.00122	CcSEcCtD
Pimecrolimus—Angioedema—Prednisolone—multiple sclerosis	0.000418	0.00121	CcSEcCtD
Pimecrolimus—Breast disorder—Methotrexate—multiple sclerosis	0.000417	0.00121	CcSEcCtD
Pimecrolimus—Hypersensitivity—Azathioprine—multiple sclerosis	0.000415	0.0012	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000415	0.0012	CcSEcCtD
Pimecrolimus—Nausea—Cladribine—multiple sclerosis	0.000412	0.00119	CcSEcCtD
Pimecrolimus—Eye disorder—Betamethasone—multiple sclerosis	0.00041	0.00119	CcSEcCtD
Pimecrolimus—Eye disorder—Dexamethasone—multiple sclerosis	0.00041	0.00119	CcSEcCtD
Pimecrolimus—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000409	0.00118	CcSEcCtD
Pimecrolimus—Back pain—Triamcinolone—multiple sclerosis	0.000407	0.00118	CcSEcCtD
Pimecrolimus—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000406	0.00117	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—multiple sclerosis	0.000399	0.00115	CcSEcCtD
Pimecrolimus—Constipation—Mitoxantrone—multiple sclerosis	0.000389	0.00113	CcSEcCtD
Pimecrolimus—Pain—Mitoxantrone—multiple sclerosis	0.000389	0.00113	CcSEcCtD
Pimecrolimus—Diarrhoea—Azathioprine—multiple sclerosis	0.000385	0.00112	CcSEcCtD
Pimecrolimus—Angioedema—Triamcinolone—multiple sclerosis	0.000385	0.00111	CcSEcCtD
Pimecrolimus—Angioedema—Methylprednisolone—multiple sclerosis	0.000384	0.00111	CcSEcCtD
Pimecrolimus—Erythema—Dexamethasone—multiple sclerosis	0.000382	0.00111	CcSEcCtD
Pimecrolimus—Erythema—Betamethasone—multiple sclerosis	0.000382	0.00111	CcSEcCtD
Pimecrolimus—Oedema—Prednisolone—multiple sclerosis	0.000374	0.00108	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000374	0.00108	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000372	0.00108	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000371	0.00107	CcSEcCtD
Pimecrolimus—Cough—Triamcinolone—multiple sclerosis	0.000367	0.00106	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000364	0.00105	CcSEcCtD
Pimecrolimus—Urticaria—Mitoxantrone—multiple sclerosis	0.000362	0.00105	CcSEcCtD
Pimecrolimus—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00036	0.00104	CcSEcCtD
Pimecrolimus—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00036	0.00104	CcSEcCtD
Pimecrolimus—Vomiting—Azathioprine—multiple sclerosis	0.000358	0.00104	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—multiple sclerosis	0.000358	0.00104	CcSEcCtD
Pimecrolimus—Arthralgia—Methylprednisolone—multiple sclerosis	0.000358	0.00103	CcSEcCtD
Pimecrolimus—Eye disorder—Prednisone—multiple sclerosis	0.000357	0.00103	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—multiple sclerosis	0.000356	0.00103	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—multiple sclerosis	0.000356	0.00103	CcSEcCtD
Pimecrolimus—Rash—Azathioprine—multiple sclerosis	0.000355	0.00103	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000355	0.00103	CcSEcCtD
Pimecrolimus—Dermatitis—Azathioprine—multiple sclerosis	0.000355	0.00103	CcSEcCtD
Pimecrolimus—Flushing—Prednisone—multiple sclerosis	0.000355	0.00103	CcSEcCtD
Pimecrolimus—Headache—Azathioprine—multiple sclerosis	0.000353	0.00102	CcSEcCtD
Pimecrolimus—Angioedema—Betamethasone—multiple sclerosis	0.000349	0.00101	CcSEcCtD
Pimecrolimus—Angioedema—Dexamethasone—multiple sclerosis	0.000349	0.00101	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—multiple sclerosis	0.000346	0.001	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—multiple sclerosis	0.000345	0.000999	CcSEcCtD
Pimecrolimus—Oedema—Triamcinolone—multiple sclerosis	0.000344	0.000994	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000344	0.000994	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000343	0.000992	CcSEcCtD
Pimecrolimus—Infection—Triamcinolone—multiple sclerosis	0.000341	0.000988	CcSEcCtD
Pimecrolimus—Infection—Methylprednisolone—multiple sclerosis	0.000341	0.000986	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000336	0.000973	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—multiple sclerosis	0.000336	0.000971	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000336	0.000971	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisolone—multiple sclerosis	0.000336	0.000971	CcSEcCtD
Pimecrolimus—Nausea—Azathioprine—multiple sclerosis	0.000335	0.000968	CcSEcCtD
Pimecrolimus—Skin disorder—Methylprednisolone—multiple sclerosis	0.000333	0.000964	CcSEcCtD
Pimecrolimus—Erythema—Prednisone—multiple sclerosis	0.000333	0.000963	CcSEcCtD
Pimecrolimus—Malnutrition—Prednisone—multiple sclerosis	0.000333	0.000963	CcSEcCtD
Pimecrolimus—Pain—Prednisolone—multiple sclerosis	0.00032	0.000925	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—multiple sclerosis	0.000317	0.000917	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000313	0.000906	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000312	0.000904	CcSEcCtD
Pimecrolimus—Oedema—Dexamethasone—multiple sclerosis	0.000312	0.000902	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000312	0.000902	CcSEcCtD
Pimecrolimus—Oedema—Betamethasone—multiple sclerosis	0.000312	0.000902	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000312	0.000902	CcSEcCtD
Pimecrolimus—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000312	0.000902	CcSEcCtD
Pimecrolimus—Infection—Dexamethasone—multiple sclerosis	0.00031	0.000896	CcSEcCtD
Pimecrolimus—Infection—Betamethasone—multiple sclerosis	0.00031	0.000896	CcSEcCtD
Pimecrolimus—Paraesthesia—Triamcinolone—multiple sclerosis	0.000309	0.000893	CcSEcCtD
Pimecrolimus—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000308	0.000891	CcSEcCtD
Pimecrolimus—Dyspnoea—Triamcinolone—multiple sclerosis	0.000306	0.000886	CcSEcCtD
Pimecrolimus—Nervous system disorder—Betamethasone—multiple sclerosis	0.000306	0.000885	CcSEcCtD
Pimecrolimus—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000306	0.000885	CcSEcCtD
Pimecrolimus—Angioedema—Prednisone—multiple sclerosis	0.000304	0.00088	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—multiple sclerosis	0.000298	0.000864	CcSEcCtD
Pimecrolimus—Urticaria—Prednisolone—multiple sclerosis	0.000297	0.000859	CcSEcCtD
Pimecrolimus—Pain—Triamcinolone—multiple sclerosis	0.000294	0.00085	CcSEcCtD
Pimecrolimus—Vomiting—Mitoxantrone—multiple sclerosis	0.00029	0.000838	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—multiple sclerosis	0.000289	0.000835	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000288	0.000833	CcSEcCtD
Pimecrolimus—Rash—Mitoxantrone—multiple sclerosis	0.000287	0.000831	CcSEcCtD
Pimecrolimus—Dermatitis—Mitoxantrone—multiple sclerosis	0.000287	0.00083	CcSEcCtD
Pimecrolimus—Headache—Mitoxantrone—multiple sclerosis	0.000285	0.000826	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000284	0.000822	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000284	0.000822	CcSEcCtD
Pimecrolimus—Arthralgia—Prednisone—multiple sclerosis	0.000283	0.00082	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000281	0.000814	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00028	0.000811	CcSEcCtD
Pimecrolimus—Paraesthesia—Dexamethasone—multiple sclerosis	0.00028	0.00081	CcSEcCtD
Pimecrolimus—Paraesthesia—Betamethasone—multiple sclerosis	0.00028	0.00081	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—multiple sclerosis	0.000278	0.000804	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—multiple sclerosis	0.000278	0.000804	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisolone—multiple sclerosis	0.000275	0.000797	CcSEcCtD
Pimecrolimus—Urticaria—Triamcinolone—multiple sclerosis	0.000273	0.00079	CcSEcCtD
Pimecrolimus—Urticaria—Methylprednisolone—multiple sclerosis	0.000272	0.000788	CcSEcCtD
Pimecrolimus—Body temperature increased—Triamcinolone—multiple sclerosis	0.000272	0.000786	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—multiple sclerosis	0.000272	0.000786	CcSEcCtD
Pimecrolimus—Oedema—Prednisone—multiple sclerosis	0.000272	0.000786	CcSEcCtD
Pimecrolimus—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000271	0.000784	CcSEcCtD
Pimecrolimus—Nausea—Mitoxantrone—multiple sclerosis	0.000271	0.000783	CcSEcCtD
Pimecrolimus—Infection—Prednisone—multiple sclerosis	0.00027	0.00078	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000269	0.000779	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000269	0.000779	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—multiple sclerosis	0.000269	0.000778	CcSEcCtD
Pimecrolimus—Pain—Betamethasone—multiple sclerosis	0.000267	0.000771	CcSEcCtD
Pimecrolimus—Pain—Dexamethasone—multiple sclerosis	0.000267	0.000771	CcSEcCtD
Pimecrolimus—Nervous system disorder—Prednisone—multiple sclerosis	0.000266	0.00077	CcSEcCtD
Pimecrolimus—Skin disorder—Prednisone—multiple sclerosis	0.000264	0.000763	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000255	0.000738	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000255	0.000738	CcSEcCtD
Pimecrolimus—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000253	0.000733	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000253	0.000731	CcSEcCtD
Pimecrolimus—Urticaria—Dexamethasone—multiple sclerosis	0.000248	0.000717	CcSEcCtD
Pimecrolimus—Urticaria—Betamethasone—multiple sclerosis	0.000248	0.000717	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000247	0.000716	CcSEcCtD
Pimecrolimus—Body temperature increased—Dexamethasone—multiple sclerosis	0.000246	0.000713	CcSEcCtD
Pimecrolimus—Abdominal pain—Dexamethasone—multiple sclerosis	0.000246	0.000713	CcSEcCtD
Pimecrolimus—Abdominal pain—Betamethasone—multiple sclerosis	0.000246	0.000713	CcSEcCtD
Pimecrolimus—Body temperature increased—Betamethasone—multiple sclerosis	0.000246	0.000713	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisone—multiple sclerosis	0.000244	0.000705	CcSEcCtD
Pimecrolimus—Pruritus—Triamcinolone—multiple sclerosis	0.000243	0.000703	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—multiple sclerosis	0.000243	0.000702	CcSEcCtD
Pimecrolimus—Pruritus—Methylprednisolone—multiple sclerosis	0.000243	0.000702	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—multiple sclerosis	0.000237	0.000685	CcSEcCtD
Pimecrolimus—Rash—Prednisolone—multiple sclerosis	0.000236	0.000682	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisolone—multiple sclerosis	0.000235	0.000681	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000235	0.00068	CcSEcCtD
Pimecrolimus—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000235	0.000679	CcSEcCtD
Pimecrolimus—Headache—Prednisolone—multiple sclerosis	0.000234	0.000677	CcSEcCtD
Pimecrolimus—Constipation—Prednisone—multiple sclerosis	0.000232	0.000672	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—RGS1—multiple sclerosis	0.000229	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CIITA—multiple sclerosis	0.000228	0.001	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000227	0.000657	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—multiple sclerosis	0.000225	0.000652	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000223	0.000979	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Methotrexate—multiple sclerosis	0.000223	0.000644	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000222	0.000642	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-G—multiple sclerosis	0.000222	0.000973	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisolone—multiple sclerosis	0.000222	0.000642	CcSEcCtD
Pimecrolimus—Pruritus—Betamethasone—multiple sclerosis	0.000221	0.000638	CcSEcCtD
Pimecrolimus—Pruritus—Dexamethasone—multiple sclerosis	0.000221	0.000638	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—multiple sclerosis	0.00022	0.000638	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TYK2—multiple sclerosis	0.00022	0.000965	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—TYK2—multiple sclerosis	0.00022	0.000965	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—TYK2—multiple sclerosis	0.00022	0.000965	CbGpPWpGaD
Pimecrolimus—Vomiting—Triamcinolone—multiple sclerosis	0.000218	0.000632	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—TYK2—multiple sclerosis	0.000218	0.000957	CbGpPWpGaD
Pimecrolimus—Vomiting—Methylprednisolone—multiple sclerosis	0.000218	0.000631	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—GPR65—multiple sclerosis	0.000217	0.000952	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—multiple sclerosis	0.000217	0.000951	CbGpPWpGaD
Pimecrolimus—Rash—Triamcinolone—multiple sclerosis	0.000217	0.000627	CcSEcCtD
Pimecrolimus—Dermatitis—Triamcinolone—multiple sclerosis	0.000216	0.000626	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—TNFAIP3—multiple sclerosis	0.000216	0.000949	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—TYK2—multiple sclerosis	0.000216	0.000948	CbGpPWpGaD
Pimecrolimus—Rash—Methylprednisolone—multiple sclerosis	0.000216	0.000625	CcSEcCtD
Pimecrolimus—Dermatitis—Methylprednisolone—multiple sclerosis	0.000216	0.000625	CcSEcCtD
Pimecrolimus—Urticaria—Prednisone—multiple sclerosis	0.000216	0.000624	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—TYK2—multiple sclerosis	0.000215	0.000944	CbGpPWpGaD
Pimecrolimus—Headache—Triamcinolone—multiple sclerosis	0.000215	0.000623	CcSEcCtD
Pimecrolimus—Headache—Methylprednisolone—multiple sclerosis	0.000215	0.000621	CcSEcCtD
Pimecrolimus—Body temperature increased—Prednisone—multiple sclerosis	0.000215	0.000621	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—multiple sclerosis	0.000215	0.000621	CcSEcCtD
Pimecrolimus—Diarrhoea—Betamethasone—multiple sclerosis	0.000213	0.000617	CcSEcCtD
Pimecrolimus—Diarrhoea—Dexamethasone—multiple sclerosis	0.000213	0.000617	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—MAPK1—multiple sclerosis	0.000213	0.000933	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—MAPK1—multiple sclerosis	0.000213	0.000933	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL7—multiple sclerosis	0.000212	0.000929	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—C4A—multiple sclerosis	0.000212	0.000929	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GPC5—multiple sclerosis	0.000211	0.000923	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—MAPK1—multiple sclerosis	0.00021	0.000919	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MMP9—multiple sclerosis	0.000208	0.000912	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000207	0.000598	CcSEcCtD
Pimecrolimus—Nausea—Triamcinolone—multiple sclerosis	0.000204	0.000591	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—multiple sclerosis	0.000204	0.00059	CcSEcCtD
Pimecrolimus—Nausea—Methylprednisolone—multiple sclerosis	0.000204	0.000589	CcSEcCtD
Pimecrolimus—MTOR—Immune System—PDCD1—multiple sclerosis	0.000203	0.000891	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Methotrexate—multiple sclerosis	0.000202	0.000585	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisone—multiple sclerosis	0.0002	0.000579	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—LINGO1—multiple sclerosis	0.0002	0.000877	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL7R—multiple sclerosis	0.000199	0.000874	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL13—multiple sclerosis	0.000199	0.000871	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR1—multiple sclerosis	0.000199	0.000871	CbGpPWpGaD
Pimecrolimus—Vomiting—Betamethasone—multiple sclerosis	0.000198	0.000574	CcSEcCtD
Pimecrolimus—Vomiting—Dexamethasone—multiple sclerosis	0.000198	0.000574	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—MAPK1—multiple sclerosis	0.000198	0.000868	CbGpPWpGaD
Pimecrolimus—Rash—Betamethasone—multiple sclerosis	0.000197	0.000569	CcSEcCtD
Pimecrolimus—Rash—Dexamethasone—multiple sclerosis	0.000197	0.000569	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—MAPK1—multiple sclerosis	0.000197	0.000862	CbGpPWpGaD
Pimecrolimus—Dermatitis—Betamethasone—multiple sclerosis	0.000196	0.000568	CcSEcCtD
Pimecrolimus—Dermatitis—Dexamethasone—multiple sclerosis	0.000196	0.000568	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000196	0.000567	CcSEcCtD
Pimecrolimus—Headache—Dexamethasone—multiple sclerosis	0.000195	0.000565	CcSEcCtD
Pimecrolimus—Headache—Betamethasone—multiple sclerosis	0.000195	0.000565	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—multiple sclerosis	0.000195	0.000855	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD28—multiple sclerosis	0.000195	0.000854	CbGpPWpGaD
Pimecrolimus—Pain—Methotrexate—multiple sclerosis	0.000194	0.000561	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—multiple sclerosis	0.000194	0.000849	CbGpPWpGaD
Pimecrolimus—Pruritus—Prednisone—multiple sclerosis	0.000192	0.000556	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—CCR2—multiple sclerosis	0.000191	0.000838	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—multiple sclerosis	0.000188	0.000826	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD28—multiple sclerosis	0.000187	0.00082	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—multiple sclerosis	0.000187	0.000818	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD28—multiple sclerosis	0.000186	0.000816	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Prednisone—multiple sclerosis	0.000186	0.000538	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000186	0.000537	CcSEcCtD
Pimecrolimus—Nausea—Dexamethasone—multiple sclerosis	0.000185	0.000536	CcSEcCtD
Pimecrolimus—Nausea—Betamethasone—multiple sclerosis	0.000185	0.000536	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—STAT3—multiple sclerosis	0.000185	0.000811	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTPRC—multiple sclerosis	0.000184	0.000805	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CBLB—multiple sclerosis	0.000183	0.000802	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—STAT3—multiple sclerosis	0.000182	0.000797	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—multiple sclerosis	0.000182	0.000797	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—multiple sclerosis	0.000182	0.000797	CbGpPWpGaD
Pimecrolimus—Urticaria—Methotrexate—multiple sclerosis	0.00018	0.000522	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—multiple sclerosis	0.000179	0.000519	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—multiple sclerosis	0.000179	0.000519	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—CD80—multiple sclerosis	0.000178	0.000779	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DPB1—multiple sclerosis	0.000177	0.000778	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IFNB1—multiple sclerosis	0.000176	0.000774	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TAGAP—multiple sclerosis	0.000173	0.00076	CbGpPWpGaD
Pimecrolimus—Vomiting—Prednisone—multiple sclerosis	0.000173	0.0005	CcSEcCtD
Pimecrolimus—Rash—Prednisone—multiple sclerosis	0.000171	0.000495	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—multiple sclerosis	0.000171	0.000495	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD40—multiple sclerosis	0.000171	0.000748	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ITGA4—multiple sclerosis	0.000171	0.000748	CbGpPWpGaD
Pimecrolimus—Headache—Prednisone—multiple sclerosis	0.00017	0.000492	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CTLA4—multiple sclerosis	0.000168	0.000738	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MAPK1—multiple sclerosis	0.000168	0.000737	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Methotrexate—multiple sclerosis	0.000167	0.000484	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—STAT3—multiple sclerosis	0.000166	0.000729	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—multiple sclerosis	0.000165	0.000726	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—MAPK1—multiple sclerosis	0.000165	0.000725	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—multiple sclerosis	0.000164	0.000717	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.000163	0.000713	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MX1—multiple sclerosis	0.000162	0.000712	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisone—multiple sclerosis	0.000161	0.000467	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—multiple sclerosis	0.000161	0.000706	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—MAPK1—multiple sclerosis	0.000161	0.000705	CbGpPWpGaD
Pimecrolimus—Pruritus—Methotrexate—multiple sclerosis	0.000161	0.000465	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000159	0.000698	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—MAPK1—multiple sclerosis	0.000158	0.000694	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRA—multiple sclerosis	0.000157	0.000689	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000156	0.000685	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Methotrexate—multiple sclerosis	0.000155	0.000449	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—STAT3—multiple sclerosis	0.000154	0.000676	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—multiple sclerosis	0.000152	0.000667	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—MAPK1—multiple sclerosis	0.000152	0.000666	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—S1PR1—multiple sclerosis	0.000152	0.000664	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—MAPK1—multiple sclerosis	0.000151	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—multiple sclerosis	0.000151	0.000662	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—STAT3—multiple sclerosis	0.000151	0.000661	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—MAPK1—multiple sclerosis	0.00015	0.00066	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK1—multiple sclerosis	0.00015	0.00066	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—TYK2—multiple sclerosis	0.00015	0.000658	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—MAPK1—multiple sclerosis	0.00015	0.000656	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—MAPK1—multiple sclerosis	0.000149	0.000653	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—VCAM1—multiple sclerosis	0.000148	0.000651	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NOD1—multiple sclerosis	0.000148	0.00065	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DQA1—multiple sclerosis	0.000148	0.000649	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GPC5—multiple sclerosis	0.000147	0.000646	CbGpPWpGaD
Pimecrolimus—Vomiting—Methotrexate—multiple sclerosis	0.000144	0.000417	CcSEcCtD
Pimecrolimus—MTOR—Immune System—MALT1—multiple sclerosis	0.000143	0.000628	CbGpPWpGaD
Pimecrolimus—Rash—Methotrexate—multiple sclerosis	0.000143	0.000414	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—multiple sclerosis	0.000143	0.000414	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—multiple sclerosis	0.000142	0.000411	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL3—multiple sclerosis	0.000142	0.000621	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRF5—multiple sclerosis	0.000141	0.000618	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK1—multiple sclerosis	0.00014	0.000614	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—MAPK1—multiple sclerosis	0.00014	0.000614	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—MAPK1—multiple sclerosis	0.00014	0.000614	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD86—multiple sclerosis	0.000139	0.000609	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—MAPK1—multiple sclerosis	0.000139	0.000609	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DQB1—multiple sclerosis	0.000139	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—MAPK1—multiple sclerosis	0.000138	0.000604	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—MAPK1—multiple sclerosis	0.000137	0.000601	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPL5—multiple sclerosis	0.000137	0.0006	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—multiple sclerosis	0.000137	0.000599	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTGER4—multiple sclerosis	0.000136	0.000597	CbGpPWpGaD
Pimecrolimus—Nausea—Methotrexate—multiple sclerosis	0.000135	0.00039	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IRF8—multiple sclerosis	0.000135	0.00059	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFIH1—multiple sclerosis	0.000135	0.00059	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-G—multiple sclerosis	0.000135	0.00059	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PGR—multiple sclerosis	0.000134	0.000588	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD86—multiple sclerosis	0.000133	0.000585	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD86—multiple sclerosis	0.000133	0.000582	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCR3—multiple sclerosis	0.000132	0.000577	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC11A1—multiple sclerosis	0.000131	0.000575	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40LG—multiple sclerosis	0.000131	0.000574	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CD28—multiple sclerosis	0.00013	0.000572	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HLA-B—multiple sclerosis	0.00013	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—multiple sclerosis	0.000129	0.000567	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—multiple sclerosis	0.000129	0.000566	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RGS1—multiple sclerosis	0.000129	0.000565	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR2—multiple sclerosis	0.000128	0.000561	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000127	0.000555	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TNFAIP3—multiple sclerosis	0.000126	0.000553	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-B—multiple sclerosis	0.000124	0.000546	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK1—multiple sclerosis	0.000124	0.000544	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—multiple sclerosis	0.000124	0.000542	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GPR65—multiple sclerosis	0.000122	0.000536	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—multiple sclerosis	0.000122	0.000533	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CNR1—multiple sclerosis	0.000118	0.000518	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CCR5—multiple sclerosis	0.000118	0.000516	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—multiple sclerosis	0.000116	0.000509	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—multiple sclerosis	0.000116	0.000507	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-A—multiple sclerosis	0.000115	0.000505	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—multiple sclerosis	0.000115	0.000504	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HLA-A—multiple sclerosis	0.000115	0.000503	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—multiple sclerosis	0.000114	0.000502	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD28—multiple sclerosis	0.000113	0.000497	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—multiple sclerosis	0.000112	0.000491	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL13—multiple sclerosis	0.000112	0.00049	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR1—multiple sclerosis	0.000112	0.00049	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPRC—multiple sclerosis	0.000111	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CCR2—multiple sclerosis	0.000111	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—multiple sclerosis	0.00011	0.000481	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	0.000108	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—multiple sclerosis	0.000108	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—multiple sclerosis	0.000108	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DPB1—multiple sclerosis	0.000108	0.000472	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOE—multiple sclerosis	0.000107	0.00047	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—multiple sclerosis	0.000107	0.000468	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL10—multiple sclerosis	0.000106	0.000466	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—multiple sclerosis	0.000106	0.000464	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DRB1—multiple sclerosis	0.000105	0.000462	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—multiple sclerosis	0.000105	0.000462	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—multiple sclerosis	0.000105	0.00046	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD28—multiple sclerosis	0.000105	0.000459	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40—multiple sclerosis	0.000104	0.000454	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ITGA4—multiple sclerosis	0.000104	0.000454	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNB1—multiple sclerosis	0.000103	0.000451	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTLA4—multiple sclerosis	0.000102	0.000447	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK1—multiple sclerosis	0.000102	0.000446	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD80—multiple sclerosis	0.000101	0.000444	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ICAM1—multiple sclerosis	0.000101	0.000443	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD80—multiple sclerosis	9.73e-05	0.000427	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD80—multiple sclerosis	9.69e-05	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK1—multiple sclerosis	9.55e-05	0.000419	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	9.54e-05	0.000418	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CD86—multiple sclerosis	9.3e-05	0.000408	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL5—multiple sclerosis	9.16e-05	0.000401	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—VCAM1—multiple sclerosis	9.01e-05	0.000395	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DQA1—multiple sclerosis	8.98e-05	0.000394	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TYK2—multiple sclerosis	8.55e-05	0.000375	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SPP1—multiple sclerosis	8.48e-05	0.000372	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DQB1—multiple sclerosis	8.4e-05	0.000368	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR5—multiple sclerosis	8.25e-05	0.000362	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TYK2—multiple sclerosis	8.18e-05	0.000359	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2RA—multiple sclerosis	8.13e-05	0.000356	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD86—multiple sclerosis	8.09e-05	0.000355	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL3—multiple sclerosis	7.96e-05	0.000349	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—multiple sclerosis	7.93e-05	0.000348	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—multiple sclerosis	7.85e-05	0.000344	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—multiple sclerosis	7.82e-05	0.000343	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—multiple sclerosis	7.74e-05	0.000339	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTGER4—multiple sclerosis	7.66e-05	0.000336	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-B—multiple sclerosis	7.55e-05	0.000331	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PGR—multiple sclerosis	7.55e-05	0.000331	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—multiple sclerosis	7.5e-05	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD86—multiple sclerosis	7.47e-05	0.000328	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—multiple sclerosis	7.43e-05	0.000326	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR3—multiple sclerosis	7.4e-05	0.000324	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—multiple sclerosis	7.4e-05	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—multiple sclerosis	7.34e-05	0.000322	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD28—multiple sclerosis	7.33e-05	0.000321	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRM—multiple sclerosis	7.26e-05	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR2—multiple sclerosis	7.2e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2RA—multiple sclerosis	7.07e-05	0.00031	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-A—multiple sclerosis	6.99e-05	0.000307	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CD80—multiple sclerosis	6.79e-05	0.000297	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—POMC—multiple sclerosis	6.73e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR1—multiple sclerosis	6.64e-05	0.000291	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCR5—multiple sclerosis	6.62e-05	0.00029	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HLA-A—multiple sclerosis	6.46e-05	0.000283	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—POMC—multiple sclerosis	6.45e-05	0.000283	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—multiple sclerosis	6.4e-05	0.00028	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRB1—multiple sclerosis	6.39e-05	0.00028	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—multiple sclerosis	6.31e-05	0.000277	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—multiple sclerosis	6.13e-05	0.000269	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—multiple sclerosis	6.03e-05	0.000264	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL10—multiple sclerosis	5.98e-05	0.000262	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD80—multiple sclerosis	5.9e-05	0.000259	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TYK2—multiple sclerosis	5.73e-05	0.000251	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—multiple sclerosis	5.73e-05	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD80—multiple sclerosis	5.45e-05	0.000239	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK1—multiple sclerosis	5.45e-05	0.000239	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—multiple sclerosis	5.32e-05	0.000233	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—multiple sclerosis	5.31e-05	0.000233	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD86—multiple sclerosis	5.23e-05	0.000229	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK1—multiple sclerosis	5.21e-05	0.000228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL5—multiple sclerosis	5.15e-05	0.000226	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	5.11e-05	0.000224	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	5.11e-05	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TYK2—multiple sclerosis	4.98e-05	0.000218	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPP1—multiple sclerosis	4.77e-05	0.000209	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—multiple sclerosis	4.77e-05	0.000209	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPC5—multiple sclerosis	4.68e-05	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—multiple sclerosis	4.67e-05	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR5—multiple sclerosis	4.64e-05	0.000203	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TYK2—multiple sclerosis	4.6e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2RA—multiple sclerosis	4.57e-05	0.0002	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—multiple sclerosis	4.51e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—multiple sclerosis	4.51e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—multiple sclerosis	4.22e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—multiple sclerosis	4.18e-05	0.000183	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—multiple sclerosis	4.16e-05	0.000182	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—multiple sclerosis	4.16e-05	0.000182	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—multiple sclerosis	4.15e-05	0.000182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—multiple sclerosis	4.01e-05	0.000176	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—multiple sclerosis	4e-05	0.000175	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.87e-05	0.00017	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD80—multiple sclerosis	3.82e-05	0.000167	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—multiple sclerosis	3.73e-05	0.000163	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—multiple sclerosis	3.72e-05	0.000163	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK1—multiple sclerosis	3.65e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—POMC—multiple sclerosis	3.63e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—multiple sclerosis	3.55e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—multiple sclerosis	3.49e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TYK2—multiple sclerosis	3.22e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—multiple sclerosis	3.22e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK1—multiple sclerosis	3.17e-05	0.000139	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—multiple sclerosis	2.99e-05	0.000131	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—multiple sclerosis	2.99e-05	0.000131	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK1—multiple sclerosis	2.93e-05	0.000128	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—multiple sclerosis	2.8e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—multiple sclerosis	2.68e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—multiple sclerosis	2.54e-05	0.000111	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—multiple sclerosis	2.44e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—multiple sclerosis	2.26e-05	9.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—multiple sclerosis	2.25e-05	9.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.23e-05	9.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—multiple sclerosis	2.1e-05	9.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—multiple sclerosis	2.09e-05	9.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK1—multiple sclerosis	2.05e-05	8.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—multiple sclerosis	1.58e-05	6.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—multiple sclerosis	1.34e-05	5.87e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POMC—multiple sclerosis	1.15e-05	5.04e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—multiple sclerosis	1.05e-05	4.6e-05	CbGpPWpGaD
